S. Kljucar

[Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients].

M. Heimesaat, K. Olms, E. von Pritzbuer, 1987, Infection.

Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections.

M. Heimesaat, J. Timm, D. Beermann, 1989, The American journal of medicine.

Efficacy and Safety of Higher-Dose Intravenous Ciprofioxacin in Infections Severe Hospital-Acquired

M. Heimesaat, J. Timm, D. Beermann, 1989 .

Does Linezolid Inhibit Its Own Metabolism?—Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients

C. Kloft, C. Joukhadar, N. Plock, 2007, Drug Metabolism and Disposition.

Effect of severity of sepsis on tissue concentrations of linezolid.

C. Kloft, C. Thallinger, R. Sauermann, 2007, The Journal of antimicrobial chemotherapy.

[The unstable thoracic wall: possibilities for treatment].

S. Kljucar, B. Friedrich, H. Redeker, 1991, Helvetica chirurgica acta.

Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study

M. Heimesaat, J. Timm, S. Kljucar, 1998, Intensive Care Medicine.

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

S. Opal, S. Lowry, W. McGee, 2004, Critical care medicine.